Skip to main content

Table 2 Therapeutics on last follow-up

From: Adult-onset autoimmune diabetes: comparative analysis of classical and latent presentation

Insulin T1DM (n = 44) LADA (n = 46) p
No insulin, n (%) 0 (0%) 4 (8.7%) 0.117
Basal insulin, n (%) 3 (6.8%) 5 (10.9%) 0.714
Premixed insulin, n (%) 6 (13.6%) 5 (10.9%) 0.689
Basal-plus, n (%) 1 (2.3%) 4 (8.7%) 0.361
Basal-bolus (MDI), n (%) 32 (72.7%) 27 (58.6%) 0.161
CSII, n (%) 2 (4.6%) 1 (2.2%) 0.612
Total daily dose (IU), median (IQR) 40.0 (32.0) 33.5 (33.0) 0.819
Total daily dose (IU)/Weight (kg), mean (± SD) 0.58 (± 0.31) 0.57 (± 0.39) 0.887
Non-insulin drugs
 Total, n (%) 9 (20.5%) 25 (54.3%) 0.001*
 Metformin, n (%) 7 (15.9%) 22 (47.8%) 0.001*
 Sulfonylureas, n (%) 0 (0%) 1 (2.2%) 1.000
 DPP4-i, n (%) 5 (11.4%) 17 (37.0%) 0.005*
 GLP1-ra, n (%) 0 (0%) 1 (2.2%) 1.000
 SGLT2-i, n (%) 0 (0%) 2 (4.3%) 0.495
  1. MDI: multiple daily injections; CSII: continuous subcutaneous insulin infusion
  2. * Chi square test